notable exception of the Spectator). Manufacturers' claims were extravagant, and Beecham's pills (containing only aloes, ginger, and soap) were, for example, promoted for indications that included "maladies of indiscretion, kidney and urinary disorders, and menstrual derangements." 2 Despite the fact that many newspapers (including the News ofthe World) refused to carry advertisements for Secret Remedies its sales exceeded the association's wildest expectations, and to meet public demand it ran to five impressions in three months. A successful sequel entitled More Secret Remedies appeared in 1911, and parliamentary concern lead to the appointment ofa select committee to examine patent medicines.
The committee sat during three sessions of parliament and heard evidence from many sources. The witnesses included Sir Joseph Beecham, who underwent a hostile public cross examination. The committee was particularly worried over claims that Sir Joseph's DEDIUTYe *anwwvnwai *Auaouau a a.au.
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pills were promoted for "maladies of indiscretion." Did this not suggest, members asked, use as an abortifacient? The select committee in its final report advised that measures were required to protect the public against injury and fraud, and it recommended that the promotion and sale of proprietary medicines should be closely regulated by the newly created Ministry of Public Health. 3 Sadly, the report was published on 4 August 1914 and was thus overshadowed .by more pressing world events. Despite this the report presaged the' passage of the venereal disease and cancer acts (which forbid promotion to the public of cures for these diseases). Moreover it conditioned 'both' the medical profession and the general public to take a more critical view of the therapeutic claims of medicines. 4 Since 1914 three concepts have revolutionised the principles and practice of therapeutics. Firstly, orthodox doctors have increasingly come to accept that while hypotheses are a sound basis for therapeutic experiments they are an insecure guide to therapeutic practice. Secondly, doctors have realised that, with singular exceptions, therapeutic anecdote provides a poor basis for clinical practice. Thirdly, and more recently, it has been recognised that no therapeutic manoeuvre is without hazard and that rational treatment entails a trade off between risk and benefit. In this article I review the effects of these three concepts in shaping current therapeutic practices and reflect on future trends.
Flawed hypotheses
Hypotheses alone are a dangerous basis for determining routine clinical practice because they are so frequently flawed. Phlebotomy was practised for nearly 2000 years for the best of contemporary motives: in Galen's time exsanguination removed evil poisons; by the early nineteenth century bleeding patients with pneumonia to syncope was intended to reverse a dangerously hyperkinetic circulation.
The twentieth century has witnessed comparable foolishness. The observation that gold salts inhibited, in vitro, the growth of Mycobacterium tuberculosis lead to the widespread use of Sanocrysin (sodium aurothiosulphate) as a treatment for tuberculosis during the 1920s and 1930s.5 The rise and decline of radical mastectomy to clear microscopic metastases in the axillary lymph nodes ofpatients with breast cancer is a postwar example of a similar well intentioned folly in which I have to confess to having been a willing, if inexpert, accomplice when a house surgeon.
In recent years our capacity for incredulity has become more sophisticated. Benoxaprofen (Opren), a non-steroidal anti-inflammatory agent, was introduced in 1980 with the promotional claim (in journals including theBMJ) that it "Has been shown, experimentally, to actually modify the arthritic disease process." This claim was based on the observation that benoxaprofen inhibited thedevelopment ofadjuvant induced arthritis in the rat' but failed to mention that other non-steroidal anti-inflammatory drugs ( used a control group to study the effects of diet,7 and during the eighteenth century Lind compared the effects of various treatments (including two oranges and a lemon a day) on the course of scurvy.8 In the nineteenth century the use of controls, usually without further description, became established in the vocabulary ofbiology.9 Controlled studies of the effects of treatment, and hence the development of therapeutics as a science, have evolved during the twentieth century.
Early clinical trials suffered from two major defects. Firstly, although some had a crossover design none used randomisation in their allocation of treatments in parallel group studies. In the Lanarkshire milk experiment, for example, the allocation of children to receive supplementary milk was left to head teachers'"; it subsequently became clear that an excess of ill nourished children had been allocated to receive extra milk."I The second defect lay in the absence of any statistical analyses of the results. Thus in the early 1930s the Medical Research Council's study of serotherapy in patients with lobar pneumonia concluded, without clear evidence to reject the null hypothesis, that while treatment had not reduced mortality in older patients it had done so in younger ones. ' Further important developments have been the attempts to ensure that while clinical trials remain scientifically rigorous they also have practical immediacy. Increasingly attention has been directed to the importance of erroneously concluding no difference between two treatments (type II errors) due to inadequate numbers; to the limited practical value of trials in groups of patients who are unrepresentative of the population as a whole33; and to the benefits of analysing trials by "treatment intent" rather than "treatment result."39 Clinical trialists, moreover, have been intensely critical of their own and others' work.4043 This has undoubtedly enhanced the scientific rigour of therapeutic research. Finally, the methodology of the randomised controlled trial has been extended to other disciplines such as surgery'44 and screening. 46 Trading risk for benefit
One of the earliest demonstrations of the adverse effects of treatment and of the difficulties facing the sceptical investigator is provided by the experience of Dr P C A Louis of the Charite Hospital, Paris. During the early years of the nineteenth century, while attempting to determine the most appropriate day to bleed patients with pneumonia,47 he was forced to the conclusion that the longer "treatment" was delayed the better the outcome for the patient. He even suggested that the outcome might be improved still further if venesection was avoided altogether. His anguish survives:
The results of my experiments on the effects of bleeding in inflammatory conditions are so little in accord with common opinion that it is only with hesitation that I have decided to publish them. The first time I analysed the relevant facts, I believed that I was mistaken, and I repeated my work but the results of this new analysis remains the same ....
Over the past 150 years doctors, patients, and the public have now become much more conditioned to the possibilities of iatrogenic disease. As in other subjects in which risk-benefit ratios are assessed40 three broad approaches have evolved. 49 Formal analysis seeks to quantify each and, by simple difference, yield a logical course of action. Large scale randomised controlled trials analysed by intention to treat are particularly appropriate for this form of risk-benefit assessment: trials of thrombolysis after acute myocardial infarction and of lipid lowering drugs in patients with hypercholesterolaemia are examples of the technique at its best. The principal weakness of formal analysis, however, is that it is difficult to apply if the risks and benefits have different end points. How do you balance the small reduction in the incidence of stroke in patients with mild to moderate hypertension treated with 1i blockers or diuretics against the much more frequent adverse effects, which may include rashes, breathlessness, impotence, and weakness? In other subjects solutions to these problems based on decision theory have been devised, but such approaches have yet to be widely accepted in medicine.40
The second method, comparative analysis, compares the toxicities ofcompounds with equivalent therapeutic properties. It has been done most successfully with non-steroidal anti-inflammatory drugs, antidepressants, and biguanide antidiabetic drugs. The underlying assumption of therapeutic equivalence, however, can be difficult to substantiate. Moreover the method BMJ VOLUME 301 may be insufficiently sensitive to changing standards. The continuing wide availability and use of butazones (phenylbutazone and oxyphenbutazone) long after less toxic non-steroidal anti-inflammatory drugs had become available is an important example.
Judgmental analysis remains the most common form of risk-benefit assessment in therapeutics. Despite its susceptibility to prejudice, bias, and personal ignorance and the difficulties it poses for medical teachers no adequate substitute has yet been found. Perhaps, in the future, doctors will become more willing to attempt to understand the language and philosophy of decision analysis.
The future of rational therapeutics
In the light of advances over the past 50 years the future of rational therapeutics should be bright. Yet attacks, many unintentional, continue to be made. Drug 56 Finally, rational therapeutics was recently attacked from a total unexpected quarter. In an editorial in Nature drug regulatory agencies in general and the American Food and Drug Administration in particular were castigated for demanding that the safety and efficacy of biotechnology products should warrant the same criteria as are expected for synthetic chemicals."' The author wrote "Is the full and expensive apparatus of these enquiries necessary when the materials on trial are intended to be identical with those produced naturally in normal human beings?" The editorial went on to describe this as "the modern equivalent of the quaint British practice of sending a man with a red flag in front of the early railway locomotives." Products of biotechnology are likely to play a major therapeutic role in the future. Nature's spokesperson is obviously (and surprisingly) unaware that biotechnological products may not be identical with their physiological counterparts even when the amino acid sequence is the same and that the administration of supraphysiological doses into non-physiological body compartments and spaces may have unsuspected consequences. Remember what happened with cortisone.
The twentieth century has seen only the beginnings of rational therapeutics. If we fail to ensure that it blossoms in the twenty first century society as a whole will be the loser.
Although the At the turn ofthe century Paris was the cutural centre ofthe avant-garde and the natural aim ofany ambitious artist. Picasso arrivedfrom Barcelona in 1900, alternating between the two citiesfor the nextfour orfiveyears. This was a time when he was to suffer not onlypoverty but depression, which he translated into the works ofhis "blue," or classical, period. The themes ofthese pictures are usually poverty and despair, the subjects social outcasts.
One ofthe Spanish pictures ofthe blue period, the pastel "The Sick Child," is reminiscent ofa Madonna and Child. But there the likeness ends. It is a picture ofdespair. The boy's face is so emaciated that his cheekbones almost protrude through theflesh and it is painful to meet his eyes. Although his mother is touchingly protective, she cannot conceal her anguish. In less sensitive hands this theme might have been sentimental, but Picasso has produced a haunting image. In particular the subtle use ofblue over its entire range complements the subject and is an ideal symbol ofpoverty and sadness. Pastel is a notoriously difficult medium but Picasso uses it here with consummate skill. It 
